Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
regional variation of aetiologies and complications in chronic kidney disease from thailand thai ckd registry
Original title: “Regional Variation of Aetiologies and Complications in Chronic Kidney Disease From Thailand (THAI-CKD Registry).”
kidney imaging for the diagnosis and follow up of a primary hyperoxaluria type 1 patient with nc nl and severe chronic kidney disease a case report with literature review
Original title: “Kidney imaging for the diagnosis and follow-up of a primary hyperoxaluria type 1 patient with NC, NL, and severe chronic kidney disease: a case report with literature review.”
uremic pancreatitis following routine initiation of losartan in advanced chronic kidney disease a case report
Original title: “Uremic pancreatitis following routine initiation of losartan in advanced chronic kidney disease: A case report.”
effects of comorbid chronic kidney disease on late onset hypophosphatasia mice under treatment with asfotase alfa
Original title: “Effects of comorbid chronic kidney disease on late-onset hypophosphatasia mice under treatment with asfotase alfa.”
beyond bioremediation a rare case of comamonas testosteroni bloodstream infection in a patient with stage 5 chronic kidney disease on maintenance hemodialysis
Original title: “Beyond Bioremediation: A Rare Case of Comamonas testosteroni Bloodstream Infection in a Patient With Stage 5 Chronic Kidney Disease on Maintenance Hemodialysis.”
renal outcomes of glp 1 receptor agonists and tirzepatide across ckd stages and metabolic phenotypes type 2 diabetes and or overweight obesity a scoping review
Original title: “Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.”
The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.
Original title: “R1 starts up with $78M, aiming for a better kidney drug”
transforming chronic kidney disease care with telemedicine expert consensus recommendations from the italian society of nephrology
Original title: “Transforming chronic kidney disease care with telemedicine: expert consensus recommendations from the Italian Society of Nephrology.”
Read our blog on healthcare IPOs of 2025 to explore how digital health and telehealth breakthroughs can transform the patient experience. This year’s innovations include Aptar Digital Health’s partnership with AstraZeneca to develop AI-powered screening algorithms for early detection of chronic kidney disease, an indication of how digital solutions are enhancing early intervention efforts. Amidst evolving venture funding and M&A activity, 2025’s initial public offerings (IPOs) highlight companies driving patient-centered, digitally-enabled healthcare solutions. Proceeds from the IPO are expected to support expansion of its affiliated practice network, new clinic openings in existing and nearby markets and continued investment in operational infrastructure. Wellgistics Health, based in Tampa, entered the market in February 2025. The company integrates digital health technology, pharmacy services and wholesale distribution, aiming to enhance patient outcomes. Wellgistics leverages strategic acquisitions, such as Wood Sage and Wellgistics LLC, along with collaborations with Tollo Health and Protega Pharmaceuticals, to streamline the pharmaceutical supply chain. With more than 20 years of expertise, Basel offers joint replacements, spine surgery, sports medicine and rehabilitation services. Its IPO will fuel regional expansion in Southeast Asia, support new technology investments and drive strategic acquisitions to broaden its footprint. Its services include womb-warming, agarwood moxibustion and Indonesian abdominal binding, along with various herbal supplements and skincare products. In fiscal 2025, the company reported $6.2 million in revenue and $1.2 million in net income, primarily from wellness services. The IPO proceeds will support research and development, expansion and strategic acquisitions.
Original title: “Healthcare IPOs of 2025: Emerging Companies to Watch - Xtalks”
dapagliflozin in patients with ckd with fabry disease
Original title: “Dapagliflozin in Patients With CKD With Fabry Disease.”